Agenus (NASDAQ:AGEN) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Agenus (NASDAQ:AGEN) from a hold rating to a buy rating in a report published on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $14.50.

Agenus Trading Down 2.6%

Shares of NASDAQ AGEN opened at $3.71 on Friday. Agenus has a 12 month low of $1.38 and a 12 month high of $7.34. The company has a 50 day simple moving average of $3.26 and a two-hundred day simple moving average of $3.76. The stock has a market cap of $142.46 million, a price-to-earnings ratio of -8.07 and a beta of 1.57.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Monday, March 16th. The biotechnology company reported $0.56 EPS for the quarter, beating the consensus estimate of ($1.27) by $1.83. The business had revenue of $34.20 million for the quarter, compared to the consensus estimate of $28.10 million. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. Analysts forecast that Agenus will post -12.55 EPS for the current year.

Hedge Funds Weigh In On Agenus

Several institutional investors and hedge funds have recently modified their holdings of AGEN. Redwood Family Wealth LLC acquired a new position in Agenus in the 4th quarter worth about $44,000. Ovata Capital Management Ltd acquired a new stake in Agenus in the fourth quarter valued at approximately $97,000. Virtu Financial LLC purchased a new stake in shares of Agenus in the fourth quarter valued at approximately $108,000. EP Wealth Advisors LLC purchased a new stake in shares of Agenus in the fourth quarter valued at approximately $31,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Agenus during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.